Related Experiment Video

Updated: Jun 14, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K

[Research Status and Progress of Third-generation EGFR-TKIs 
in Elderly Patients with Non-small Cell Lung Cancer]

Xue Chen1,2, Yijia Sun1,2, Lihong Zhang1,2

  • 1Kunming Medical University, Kunming 650500, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|June 12, 2025
PubMed

Insights

Third-generation EGFR-TKIs are effective and safe for elderly patients with advanced non-small cell lung cancer (NSCLC). While combination therapies may improve survival, their increased toxicity requires careful consideration.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Advanced non-small cell lung cancer (NSCLC) with EGFR mutations is typically treated with third-generation EGFR-TKIs.
  • Limited data exists on elderly NSCLC patients due to low clinical trial enrollment.

Purpose of the Study:

  • To review the efficacy and safety of third-generation EGFR-TKIs in elderly NSCLC patients.
  • To compare monotherapy versus combination therapies in this population.

Main Methods:

  • Integration of subgroup analyses and pre-specified objectives from prospective and retrospective studies.
  • Focus on elderly patients with advanced NSCLC harboring sensitive EGFR mutations.

Main Results:

  • Third-generation EGFR-TKIs demonstrate comparable efficacy in elderly patients to younger populations.
  • These agents are generally well-tolerated in the elderly NSCLC population.
  • Combination therapies may offer extended survival but with increased toxicity.

Conclusions:

  • Third-generation EGFR-TKIs are a viable treatment option for elderly patients with advanced NSCLC.
  • Careful risk-benefit assessment is crucial when considering combination therapies due to potential toxicity.
Keywords:
Epidermal growth factor receptor-tyrosine kinase inhibitorsLung neoplasmsResearch progressResearch status

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
147
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K